Table 3 Univariate analysis of OS in relation to clinicopathological factors in 117 patients with gastric cancer.
| Factor | N | OS | |
|---|---|---|---|
| N (%) | p Value | ||
| Sex | |||
| Male | 84 | 19 (22.6) | 0.1837 |
| Female | 33 | 4 (12.1) | |
| Depth of invasion | <0.001 | ||
| pT1–2 | 84 | 3 (3.6) | |
| pT3–4 | 33 | 20 (60.1) | |
| Lymph node metastasis | <0.001 | ||
| Negative | 73 | 2 (2.7) | |
| Positive | 44 | 21 (47.7) | |
| TNM stage | <0.001 | ||
| I | 78 | 1 (1.3) | |
| II–IV | 39 | 22 (56.4) | |
| Venous invasion | <0.001 | ||
| Negative | 100 | 14 (14.0) | |
| Positive | 17 | 9 (52.9) | |
| LVI‐HE | <0.001 | ||
| Negative | 88 | 6 (6.8) | |
| Positive | 29 | 17 (58.6) | |
| LVI‐IHC | 0.0001 | ||
| Negative | 75 | 7 (9.3) | |
| Positive | 42 | 16 (38.1) | |
| LVD (mean LVD/field) | 0.0180 | ||
| <12 | 67 | 8 (11.9) | |
| ⩾12 | 50 | 15 (30.0) | |
LVD, podoplanin positive lymph vessel density; LVI‐HE, lymph vessel invasion detected by haematoxylin and eosin staining; LVI‐IHC, lymph vessel invasion detected by podoplanin immunohistochemistry; OS, overall survival.